Literature DB >> 17657184

[Lymphocytic infiltrate of the dermis preceding typical Sweet's syndrome].

P Boeckler1, G Noacco, S Maradeix, E Heid, D Lipsker, B Cribier.   

Abstract

BACKGROUND: The histologic criteria for Sweet's syndrome consist in prominent oedema of the dermis and a diffuse infiltrate of numerous neutrophils with leukocytoclasis without vasculitis in the superficial and the deep dermis. Several comorbidities have been observed in patients with Sweet's syndrome, particularly hemo-proliferative diseases. PATIENTS: We report the cases of two men aged 60 and 75 years with Sweet's syndrome associated in one case with myelodysplasia and in the other with chronic lymphocytic leukemia. These two patients had typical edematous plaques highly evocative of Sweet's syndrome. However, histological examination revealed superficial and deep perivascular lymphocytic infiltrate in the dermis on 5 occasions before the typical neutrophilic dermatosis of Sweet's could be diagnosed after respectively 2 and 4 years of progression. DISCUSSION: Histological findings in Sweet's syndrome are characteristic and constitute a major diagnostic factor. However, these two cases show that a lymphocytic infiltrate can occur months or even years before the appearance of typical neutrophilic infiltrate in patients with Sweet's syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657184     DOI: 10.1016/s0151-9638(07)89269-6

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

1.  Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.

Authors:  Lisa Ghoufi; Nicolas Ortonne; Saskia Ingen-Housz-Oro; Walid Barhoumi; Edouard Begon; Corinne Haioun; Cécile Pautas; Florence Beckerich; Christine Robin; Pierre Wolkenstein; Catherine Cordonnier; Olivier Chosidow; Andréa Toma
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.